GSK Acquires Affinivax, Inc.

AstraZeneca Acquires Icosavax

December 12, 2023

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Icosavax, a Seattle-based clinical-stage biopharmaceutical company, in a cash tender offer valuing the deal at approximately $0.8bn upfront and up to $1.1bn including contingent payments. The acquisition brings Icosavax's virus‑like particle (VLP) platform and Phase III‑ready combination RSV/hMPV vaccine candidate IVX‑A12 into AstraZeneca's Vaccines & Immune Therapies late‑stage pipeline to strengthen respiratory vaccine capabilities for older adults and vulnerable populations.

Sanofi to Acquire Vicebio for Up to $1.6 Billion

July 25, 2025

Biotechnology

Sanofi will acquire clinical-stage biopharmaceutical company Vicebio in a deal worth up to $1.6 billion, including $1.15 billion upfront and $450 million in milestone payments. Vicebio, created by Medicxi using the University of Queensland's Molecular Clamp technology, develops multivalent vaccines targeting respiratory viruses and recently advanced a bivalent RSV/hMPV candidate into Phase 1 trials.

Vaccitech plc Acquires Avidea Technologies to Expand SNAPvax Pipeline

December 13, 2021

Biotechnology

Vaccitech plc acquired US-based Avidea Technologies, Inc. for approximately $40 million (about $12.5M cash and $27.5M in Vaccitech ADS) plus potential milestone payments. The deal brings Avidea's SNAPvax™ nanoparticle platform and early-stage product candidates into Vaccitech's pipeline, expands Vaccitech's U.S. R&D presence, and adds Avidea co-founders to Vaccitech's scientific team.

Sanofi Acquires Amunix Pharmaceuticals

December 21, 2021

Biotechnology

Sanofi has entered into an agreement to acquire Amunix Pharmaceuticals for an upfront payment of approximately $1.0 billion plus up to $225 million in potential development milestones. The acquisition gives Sanofi Amunix’s Pro‑XTEN/XPAT/XPAC masking technology and a pipeline of conditionally activated T‑cell engagers and cytokine therapies (including lead candidate AMX‑818), expanding Sanofi’s immuno‑oncology capabilities.

Pfizer Acquires Amplyx Pharmaceuticals

April 28, 2021

Biotechnology

Pfizer Inc. acquired Amplyx Pharmaceuticals, a privately held clinical-stage biotechnology company developing the antifungal candidate fosmanogepix (APX001). The deal expands Pfizer's anti-infectives pipeline and secures Amplyx's lead and early-stage assets to advance development of novel antifungal and antiviral therapies.

GSK Acquires Aiolos Bio for Up to $1.4 Billion

January 9, 2024

Biotechnology

GSK will acquire clinical-stage biopharmaceutical company Aiolos Bio for $1 billion upfront and up to $400 million in regulatory milestone payments, gaining access to AIO-001, a long-acting anti-TSLP monoclonal antibody advancing into Phase II for asthma. The deal expands GSK's respiratory biologics pipeline with a potential best-in-class therapy that may offer dosing as infrequently as every six months.